Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD reviews OS-CAL

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline has agreed to modify disclaimer language for OS-CAL following a review by the National Advertising Division of the Council for Better Business Bureaus, according to a June 8 release from the watchdog group. NAD determined the claim, "Only OS-CAL is proven to help reduce risk of hip fractures by 29%," was substantiated by the results of the Women's Health Initiative. However, NAD recommended the company drop the "among calcium supplements" disclaimer for the claim "to avoid any implication that the study compared competing calcium supplements," the release says. The review was part of NAD's ongoing monitoring program. The self-regulatory group notes its review of dietary supplement advertising has expanded because of a series of grants from supplement trade group the Council for Responsible Nutrition (1"The Tan Sheet" April 30, 2007, p. 13)...

You may also be interested in...

In First CRN-Funded Case, NAD Questions CH-Alpha Cartilage Health Claim

The National Advertising Division, in its first investigation supported by the Council for Responsible Nutrition, recommended Gelita Health Products discontinue or modify a health claim for its CH-Alpha product

Crunch Time For Protection Of New Therapeutic Uses In Europe

The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.

Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts